2025-02-15 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

**0. Executive Summary:**

Johnson & Johnson (JNJ), a multinational healthcare corporation, has underperformed the S&P 500 (VOO) significantly over the analyzed period. While exhibiting relatively stable profitability and revenue, its growth trajectory lags behind the broader market.  Recent price movements indicate short-term weakness, however long-term prospects remain dependent on various factors.  The substantial negative expected return relative to the S&P 500 raises concerns about long-term outperformance.

**1. Performance Comparison with S&P 500 (VOO):**

Johnson & Johnson is a diversified healthcare company that manufactures medical devices, pharmaceuticals, and consumer products.

* **JNJ Cumulative Return:** 33.02%
* **VOO Cumulative Return:** 121.84%
* **Return Difference:** -88.8%
* **Relative Rank (based on historical range):** 8.7% (This means JNJ's underperformance relative to VOO is in the 8.7th percentile of its historical underperformance range.)

The table below shows the Compound Annual Growth Rate (CAGR), Maximum Drawdown (MDD), Alpha, Beta, and market capitalization (Cap) for various periods.  Note that Alpha and Beta are calculated relative to a benchmark, which is not specified. A negative Alpha indicates underperformance relative to the benchmark after adjusting for Beta. A Beta close to 1 suggests similar volatility to the market, while lower Beta values indicate lower volatility.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 34.0% | 0.2% | 6.0% | -0.1 | 277.3 |
| 2016-2018  | 12.0% | 10.8% | -7.0% | 0.0 | 263.1 |
| 2017-2019  | 21.0% | 10.8% | -9.0% | 0.7 | 305.7 |
| 2018-2020  | 12.0% | 10.8% | -16.0% | 0.4 | 338.8 |
| 2019-2021  | 28.0% | 7.9% | -43.0% | 0.4 | 377.6 |
| 2020-2022  | 17.0% | 7.9% | 9.0% | 0.4 | 400.1 |
| 2021-2023  | -11.0% | 6.9% | -34.0% | 0.4 | 365.8 |
| 2022-2024  | -25.0% | 8.0% | -58.0% | 0.3 | 348.2 |
| 2023-2025  | -6.0% | 8.0% | -68.0% | 0.3 | 375.9 |


**2. Recent Price Movement:**

* **Closing Price:** $156.15
* **Previous Close:** $157.25
* **Change:** -$1.10 (-0.7%)
* **5-day Moving Average:** $155.81
* **20-day Moving Average:** $151.95
* **60-day Moving Average:** $149.26

The price is below all three moving averages, suggesting a short-term bearish trend.  The recent price drop is relatively small and should not be interpreted as a "crash"

**3. Technical Indicators:**

* **RSI:** 59.39 (Neither overbought nor oversold)
* **PPO:** 0.29 (Positive, suggesting upward momentum, although weak)
* **Relative Strength Change (20-day):** -0.7 (Short-term weakening trend)
* **Expected Return (vs. S&P 500, long-term):** -302.0% (This indicates a significant underperformance expectation relative to the S&P 500 over a long-term horizon (2 years or more). This is a very substantial negative value and requires further investigation to understand its basis.)

**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
|------------|------|---------------|
| 2024-10-23 | $1.12 | $22.47B       |
| 2024-07-25 | $1.95 | $22.45B       |
| 2024-05-01 | $1.35 | $21.38B       |
| 2024-02-16 | $1.68 | $21.39B       |
| 2023-10-27 | $10.32 | $21.35B       |

EPS is volatile quarter to quarter,  requiring further analysis to determine the underlying reasons for the fluctuations. Note the unusually high EPS in 2023-10-27, which drastically skews the data. Revenue appears relatively stable.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $22.52B | 68.35%       |
| 2024-09-30 | $22.47B | 69.01%       |
| 2024-06-30 | $22.45B | 69.40%       |
| 2024-03-31 | $21.38B | 69.55%       |
| 2023-12-31 | $21.39B | 68.23%       |

Revenue is relatively stable, and profit margins are consistently high.


**Capital and Profitability:**

| Quarter | Equity   | ROE     |
|---------|----------|---------|
| 2024-12-31 | $71.49B | 4.80%  |
| 2024-09-30 | $70.16B | 3.84%  |
| 2024-06-30 | $71.54B | 6.55%  |
| 2024-03-31 | $70.02B | 4.65%  |
| 2023-12-31 | $68.77B | 5.89%  |

Equity and ROE show some fluctuation but remain generally stable.


**6. Overall Analysis:**

JNJ shows consistent profitability and relatively stable revenue. However, its return significantly lags behind the S&P 500, indicated by a large negative Alpha and a substantially negative expected return relative to the S&P 500. The short-term price action suggests weakness, but the long-term outlook depends heavily on factors not fully captured in the provided data, such as future earnings growth, competitive landscape developments and market sentiment.  The highly negative expected return (-302%) demands further scrutiny of the methodology used to generate this figure.  The data provided suggests that JNJ is a relatively stable, but low-growth investment compared to the broader market.  Further investigation into the underlying causes of the underperformance and the methodology behind the projected return is critical before making any investment decisions.
